You are here: Industry Insights > IO

News List

Immuno-Oncology: Current Market Landscape and Future Trends（2） Neeta Ratanghayra
September 18, 2024
CAR-T Therapy & Antibody–Drug Conjugates.
Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData expresspharma
April 23, 2021
Class-wide sales of IO are expected to grow to 72.2 per cent of the market, contributing $3.8 billion to global sales in 2029 and growing at a CAGR of 28 per cent.
Doctors keen to adopt novel biomarkers for immuno-oncology regimens: GlobalData expresspharma
March 16, 2021
The most promising or anticipated biomarker among high-prescribing physicians in the seven major markets was identified to be measures of tumour mutational burden.
Zydus, XOMA Enter IO Agreement contractpharma
March 10, 2020
To advance an IL-2-based immuno-oncology drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody.
Pfizer’s new partnership focuses on digitising clinical trials pharmaceutical-technology
February 21, 2019
Pfizer has partnered with non-profit healthcare system Ochsner Health System to develop digital models that aim to improve clinical trials.....
Astellas Pharma Acquires Potenza Therapeutics contractpharma
December 18, 2018
Astellas Pharma Inc. has exercised its exclusive option to acquire Potenza Therapeutics, Inc., paying $164.6 million upfront and additional payments of as much as $240.1 million, depending on the progress of various programs.